TA
MDGL icon

Tiedemann Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Tiedemann Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$218K Hold
1,492
– – 0.01% 256
2023
Q2 		$345K Hold
1,492
– – 0.01% 195
2023
Q1 		$361K Hold
1,492
– – 0.02% 188
2022
Q4 		$433K Buy
+1,492
New +$146K 0.02% 165

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tiedemann Advisors's MDGL Position: Q3 2023 in Review

Tiedemann Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2023 at 1,492 shares worth $218K. The position accounts for 0.01% of the portfolio, ranked #256.

Tiedemann Advisors first reported a position in MDGL in Q4 2022 and has held it in 4 quarters since. The position peaked at $433K in Q4 2022. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

  • Tiedemann Advisors held 1,492 shares of Madrigal Pharmaceuticals worth $218K as of Q3 2023.
  • Tiedemann Advisors left its Madrigal Pharmaceuticals share count unchanged in Q3 2023.
  • Madrigal Pharmaceuticals made up 0.01% of Tiedemann Advisors's portfolio in Q3 2023, its #256 holding.
  • Tiedemann Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
  • Tiedemann Advisors's Madrigal Pharmaceuticals position peaked at $433K in Q4 2022.
  • 205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on Tiedemann Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.